CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has granted equity awards to 18 new non-executive employees as part of its 2025 Inducement Plan, reinforcing the biopharmaceutical company’s strategy to attract and retain top talent amid its ongoing commercial expansion.
The awards, approved November 1 by Madrigal’s independent Compensation Committee, were issued under Nasdaq Listing Rule 5635(c)(4), which allows equity grants outside of shareholder-approved plans as an employment incentive. In total, the new hires received 7,301 time-based restricted stock units that vest in four equal installments over four years, contingent upon continued employment.
The equity inducements are designed to align employee interests with long-term shareholder value as Madrigal continues advancing its breakthrough liver disease treatment, Rezdiffra (resmetirom). The once-daily oral therapy is the first and only medication approved by both the U.S. Food and Drug Administration and the European Commission for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2 to F3).
Madrigal is also conducting a Phase 3 outcomes trial evaluating Rezdiffra in patients with compensated MASH cirrhosis (F4c), a key step in expanding the drug’s potential indications.
By linking equity to employee tenure and performance, Madrigal aims to strengthen its workforce during a critical phase of growth in the rapidly evolving MASH therapeutic market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.